Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment

Nomata, Koichiro; Noguchi, Mitsuru; Kanetake, Hiroshi; Tsuda, Nobuo; Hayashi, Mikio; Yamashita, Shuji; Sakuragi, Tsutomu; Kusaba, Yasuyuki; Shindo, Kazuhiko

doi:10.1007/s00280-002-0487-6

Cited by 22 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in another study comparing 11 instillations of epirubicin during 12 mo to 9 instillations during 6 mo, no difference was found [18]. Likewise, no difference was found in a study comparing 19 instillations of epirubicin during 12 mo to 12 instillations during 5 mo [21]. In all three of these trials there is a possible dilution of the size of the treatment effect due to recurrences in the long-term treatment arm prior to starting the long-term instillations at 5 or 6 mo.…”

Section: If One Immediate Instillation Is Not Given How Long Should mentioning

confidence: 92%

“…One year of chemotherapy-Three trials using various drugs compared short-term instillations of 5-6 mo to instillations during 1 yr [13,18,21]. In one study, fewer patients had recurrence with 12 mo of MMC or Adriamycin (15 instillations) as compared to 6 mo of treatment (9 instillations), 41.2% versus 55.8% (p = 0.01) [13].…”

Section: If One Immediate Instillation Is Not Given How Long Should mentioning

confidence: 99%

See 1 more Smart Citation

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

2008

View full text Add to dashboard Cite

Objectives-Intravesical chemotherapy has been studied in randomized clinical trials for >30 yr; however, the optimal schedule and duration of treatment are unknown. The objective is to determine the effect of schedule and duration of intravesical chemotherapy on recurrence in patients with stage Ta T1 bladder cancer.Methods-A systematic review was conducted of the published results of randomized clinical trials that compared intravesical instillations with respect to their number, frequency, timing, duration, dose, or dose intensity.

show abstract

Section: If One Immediate Instillation Is Not Given How Long Should mentioning

confidence: 92%

Section: If One Immediate Instillation Is Not Given How Long Should mentioning

confidence: 99%

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

2008

View full text Add to dashboard Cite

show abstract

“…The dwell time was at least 1 h in 9 studies. However, 4 studies [17,25,30,31] did not describe the details of dwell time.…”

Section: Study Characteristicsmentioning

confidence: 96%

“…Among these studies, two trials [17,33] were simple randomization, four trials [11,25,31,32] were stratified randomization and a dynamic method was used in the trial by Kuroda in 2004 [29] . Other five trials [21,24,26,27,30] only described "randomly assigned" without sufficient information for judgment, so were evaluated as "unclear". The patients in the last trial by Hendricksen in 2008 [28] were allocated according to the date of TURBT, so was judged as "high risk of bias".…”

Section: Risk Of Bias In Included Studies 231 Allocation (Selectionmentioning

confidence: 99%

Long-term versus short-term introvesical chemotherapy in patients with non-muscle-invasive bladder cancer: A systematic review and meta-analysis of the published results of randomized clinical trials

Teng

Xing

Liu

et al. 2014

J. Huazhong Univ. Sci. Technol. [Med. Sci.]

View full text Add to dashboard Cite

In order to assess the effect of long-term versus short-term intravesical chemotherapy in preventing the recurrence of patients with non-muscle-invasive bladder cancer, we searched several databases with words as mesh terms and free text words to find all eligible randomized clinical trials (RCTs) for the comparison of the two strategies of instillation durations. "Observed-Expected events research (O-E)" and "Variance (V)" for calculating hazard ratio (HR) were used in Revman 5.2 software recommended by Cochrane Collabration for data analysis. Sensitivity and subgroup analysis were selected to minish heterogeneity. GRADEpro 3.6 profile recommended by Cochrane Collabration was employed for quality assessment of analyses. Finally, 13 eligible RCTs with 4216 patients were included in this review and 16 comparisons from 13 trials were involved for analysis. The pooled analysis revealed no significant difference between long-term and short-term duration [HR=0.99, 95% CI (0.89, 1.11), P=0.89]. Within the subgroup analysis, patients benefited from long-term instillations with a start regimen of one immediate instillation [HR=0.83, 95% CI (0.69, 1.00), P=0.05]. But patients were not suitable to receive long-term instillations with epirubicin (EPI) [HR=1.01, 95% CI (0.91, 1.13), P=0.78]. The progression rate was not reduced after long-term instillations [HR=0.96, 95% CI (0.66, 1.39), P=0.82]. From our results, patients should not receive introvesical chemotherapy more than half a year. In contrast, patients with one immediate instillation are preferred to have a long-term duration at least one year. Long-term instillations can not reduce the progression rate.

show abstract

“…This adjuvant does not specifically target the disease. It has also been shown that intravesical chemotherapy could be effective in decreasing the short-term incidence of tumour recurrence (1,7). No evidence was found however that such treatment could decrease the long-term incidence of tumor recurrence, according to 60-to 77-month follow-up study (1).…”

Section: Introductionmentioning

confidence: 99%

Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma

Fortin

Orlova²,

Malmström³

et al. 2007

Int J Mol Med

View full text Add to dashboard Cite

Abstract. The direct instillation of radiolabelled conjugates in the urinary bladder is a promising path for the treatment of bladder carcinoma. The targeting of HER2/neu receptors expressed on the surface of many bladder carcinoma cells shows potential to be developed as a therapeutic strategy, and patients identified with a high risk of progression may benefit from adjuvant targeted radionuclide therapy. A phage-display selected Affibody molecule (Z HER2:342 ) which binds to HER2/ neu with picomolar affinity, can be used for targeting HER2/ neu-expressing bladder carcinomas. A DOTA-derivative of Z HER2:342 , designated as DOTA-Z HER2:342 -3, is considered as a suitable targeting agent for therapy. The DOTA chelator provides stable labelling with radiometals, and the low molecular weight (7.2 kDa) of the DOTA-Z HER2:342 -3 compound is expected to enable efficient tumor penetration. DOTA-Z HER2:342 -3 was radiolabelled with 90 Y and 177 Lu in 1 M ammonium acetate buffer, at pH 5.5, and in the presence of ascorbic acid. Nearly quantitative labelling yields were achieved for both nuclides after 15 min of incubation at 60˚C. After chelation, the conjugates retained their capacity to specifically bind to HER2/neu-expressing SKOV-3 cells. The radiolabelled affibody conjugate (DOTA-Z HER2:342 -3) demonstrated high antigen-binding capacity and good cellular retention. Biodistribution in normal mice demonstrated low uptake in all organs and tissues except for kidneys.

show abstract

Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment

Abstract: This analysis indicated that extended prophylactic maintenance instillation of EPI was not significantly effective in reducing bladder cancer recurrence.

Cited by 22 publications

References 12 publications

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

Long-term versus short-term introvesical chemotherapy in patients with non-muscle-invasive bladder cancer: A systematic review and meta-analysis of the published results of randomized clinical trials

Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma

Contact Info

Product

Resources

About